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Abstract
 
Anterior pituitary hormone secretion is mainly regulated by
hypothalamic releasing factors, which reach the pituitary
via portal vessels. It has been demonstrated recently that
these peptides can also be produced by the pituitary itself,
thus possibly modulating hormone secretion in a paracrine/
autocrine fashion. The object of this study was to seek evi-
dence for the synthesis and secretion of corticotropin-releas-
ing hormone (CRH) within the anterior pituitary and to
ascertain its biological relevance. Messenger RNA from
adult rat anterior pituitary fragments and cell cultures was
reverse transcribed and subjected to PCR amplification us-
ing primers specific to the rat CRH gene. As in the hypo-
thalamus, a single 232-bp band was obtained. The corre-
spondence of the amplified fragment to the sequence of the
CRH gene was confirmed by Southern blotting and restric-
tion enzyme digestion. Combined in situ reverse transcrip-
tion-PCR amplification/immunocytochemistry demonstrated
the presence of CRH mRNA in corticotropes. Medium from
anterior pituitary primary cultures contained 
 
z
 
 7 pg/
 
m
 
g
protein of CRH immunoreactivity which presented the same
chromatographic profile on HPLC as the mature CRH pep-
tide. Incubation of anterior pituitary cells with an antibody
directed against CRH markedly reduced basal ACTH secre-
tion compared with serum-treated control wells (0.89
 
6
 
0.11
vs. 1.74
 
6
 
0.14 ng/200,000 cells in control wells after 1 h,
 
P 
 
, 
 
0.05; 1.17
 
6
 
0.10 vs. 2.16
 
6
 
0.39 ng/200,000 cells after
2 h,
 
 P 
 
, 
 
0.05; 1.45
 
6
 
0.12 vs. 3.12
 
6
 
0.61 ng/200,000 cells after
3 h,
 
 P 
 
, 
 
0.05). Further, the ACTH response to potassium
and to forskolin was markedly blunted by the CRH antise-
rum as well as by the CRH antagonist, 
 
a
 
-helical CRH(9-41).
In conclusion, this study demonstrates the presence of CRH
mRNA in normal rat corticotropes and the secretion of the
mature peptide by the anterior pituitary, pointing to the
production of CRH at the site of its target cells. In addition,
intrapituitary CRH contributes in a paracrine/autocrine
fashion to ACTH secretion. (
 
J. Clin. Invest.
 
 1998. 101:2478–
2484.) Key words: hypothalamic releasing factors 
 
•
 
 cortico-
tropes 
 
•
 
 gene expression 
 
•
 
 tissue distribution
 
Introduction
 
It is well known that anterior pituitary function is regulated
both by hypothalamic neuropeptides and peripheral hormones
which reach the gland via portal vessels and the systemic circu-
lation, respectively. In addition to these blood-borne regula-
tors, substances produced within the gland itself have been
credited with an increasing importance in the regulation of
adenohypophyseal hormone synthesis and secretion (1–3).
The anterior pituitary has in fact been found to contain a wide
variety of bioactive peptides, such as growth factors, cytokines,
brain-gut peptides, and vasogenic substances (2, 3). The func-
tion of some of these substances within the anterior pituitary
has been well documented, as for example for the vasoactive
intestinal peptide (4), while it awaits definition for others.
Quite recently, several members of another group of peptides,
the hypothalamic releasing factors, have been demonstrated in
the anterior pituitary. Their presence within the gland itself
could represent yet another facet of adenohypophyseal physi-
ology.
So far, conclusive evidence has been put forward for the
synthesis and secretion of thyrotropin-releasing hormone (5,
6), somatostatin (7, 8), growth hormone–releasing hormone (8,
9), gonadotropin-releasing hormone (10, 11), and vasopressin
(12, 13) by normal anterior pituitary cells. As regards corti-
cotropin-releasing hormone (CRH),
 
1
 
 mRNA for this hormone
has been found in the whole pituitary gland (14) but whether
this signal derives from the adenohypophysis or the posterior
pituitary, which cells are responsible for CRH gene expression,
and whether locally produced CRH in fact modulates cortico-
trope secretion have not been established. Therefore, we de-
cided to look for evidence of synthesis of CRH by the anterior
pituitary and, if this is the case, to investigate its biological rel-
evance towards ACTH secretion.
 
Methods
 
RNA extraction and PCR amplification.
 
Adult male Sprague-Dawley
rats (200–220 g body wt) were killed, and pituitaries were collected
and dissected carefully into anterior and posterior lobes. Total RNA
was extracted from pituitary fragments and dispersed anterior pitu-
itary cells after 4 d in culture (vide infra), hypothalami (positive con-
trol), and liver (negative control) using the guanidinium-isothio-
cyanate protocol (15) (Tri Reagent; Molecular Research Center,
Cincinnati, OH). RNA was quantitated and 1 
 
m
 
g was reverse tran-
scribed using the GeneAmp RNA PCR kit (Perkin Elmer, Foster
City, CA). Reverse-transcribed cDNA was amplified with primers lo-
cated on exon 2 of the rat CRH gene (14) (upstream primer: bp 306-
322, downstream primer: bp 523-539). The amplification protocol was
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as follows: 4 min at 95
 
8
 
C, 2 min at 56
 
8
 
C, and 2 min at 72
 
8
 
C for 1 cycle;
40 s at 95
 
8
 
C, 30 s at 56
 
8
 
C, and 1 min at 72
 
8
 
C for 35 cycles followed by
a 15-min extension at 72
 
8
 
C. One-tenth of the obtained PCR product
was electrophoresed on a 4% agarose gel and stained with ethidium
bromide.
Integrity of mRNA was verified by reverse-transcribing and
amplifying the same samples with primers for the glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene which were specifically
designed to span an intron of 114 bp (16). The amplification protocol
was as follows: 20 s at 94
 
8
 
C, 5 s at 59
 
8
 
C, and 1 min and 10 s at 72
 
8
 
C
with a progressive increment of 0.01 s/cycle for 9 cycles; 20 s at 94
 
8
 
C,
10 s at 58
 
8
 
C, and 1 min and 10 s at 72
 
8
 
C with an increment of 0.01 s/cy-
cle for 25 cycles followed by 10 s at 58
 
8
 
C and a 15-min extension at
72
 
8
 
C. Amplification of reverse-transcribed cDNA gives rise to a 240-bp
band whereas a band arising from genomic DNA would be 354 bp in
length. Genomic contamination was also excluded by carrying out
both CRH and GAPDH PCR amplification in samples not subjected
to reverse transcription.
 
Restriction enzyme digestion and Southern blotting.
 
After ampli-
fication with CRH primers, PCR products were purified and concen-
trated using the JetPure PCR purification kit (Genomed, Bad Oeyn-
hausen, Germany) and one-third of the purified DNA incubated for 2 h
at 37
 
8
 
C with either PstI (Amersham International, Little Chalfont,
UK) or HaeIII (New England Biolabs, Beverly, MA). Digests were
then electrophoresed and stained.
Another aliquot of the purified DNA was electrophoresed on a
4% agarose gel and transferred to a Nytran membrane (Hybond;
Amersham International). The membrane was prehybridized in 6
 
3
 
SSC, 0.5% SDS, 5
 
3
 
 Denhardt’s solution, 0.01 M Na phosphate, 1 mM
EDTA, and 100 
 
m
 
g/ml salmon sperm DNA for 2 h at 50
 
8
 
C. An oligo-
probe complementary to bp 479–503 of the rat CRH gene (14) was 5
 
9
 
end-labeled using T4 polynucleotide kinase (New England Biolabs)
and [
 
g
 
-
 
32
 
P]ATP (Amersham International). The labeled oligoprobe
was then added to the same solution and hybridization was carried
out for 4 h at 50
 
8
 
C. The membrane was washed three times for 2 min
at room temperature and twice at 50
 
8
 
C in 2
 
3
 
 SSC, 0.1% SDS, there-
after 2 min at room temperature and 2 min at 50
 
8
 
C in 0.5
 
3
 
 SSC, 0.2%
SDS. The filter was exposed overnight to an x-ray film (X-Omat AR;
Eastman Kodak, Rochester, NY).
 
Combined in situ reverse transcription-PCR amplification/immu-
nocytochemistry.
 
In situ reverse transcription-PCR was performed
with a slight modification of published protocols (17, 18). Dispersed
pituitary cells (vide infra) were thoroughly washed with PBS and
plated onto silane-coated slides at a density of 200,000 cells/section.
Cells were fixed in 10% buffered formalin (Sigma Chemical Co., St.
Louis, MO) and digested overnight with RQ1 DNase (8 U/section)
(Promega, Madison, WI). We found that permeabilization of cell
monolayers with proteinase K (even with concentrations as low as 0.5
 
m
 
g/ml) increased nonspecific stain, thus this step was omitted. Re-
verse transcription was performed as described above, whereas PCR
amplification was shortened to 20 cycles and carried out in the pres-
ence of 200 
 
m
 
M each dATP, dCTP, and dGTP, 190 
 
m
 
M dTTP, and
10 
 
m
 
M digoxigenin dUTP (Boehringer Mannheim, Indianapolis, IN).
Detection of the digoxigenin-tagged PCR product was performed ac-
cording to the manufacturer’s instructions (Boehringer Mannheim)
with the addition of 0.24 mg/ml levamisole (Sigma Chemical Co.) to
the chromagen solution. Negative controls were: omission of reverse
transcriptase; omission of primers; and omission of 
 
Taq
 
 polymerase.
Immunocytochemistry was performed on the same specimens using
an antibody against ACTH raised in rabbits (code No. N1531;
DAKO Corp., Carpinteria, CA) and a three-step biotin-streptavidin-
peroxidase detection system (LSAB 2 kit; DAKO Corp.). Normal
rabbit serum (NRS) obtained from the same supplier was used to
check for nonspecific staining.
 
Modulation of ACTH secretion from anterior pituitary primary
cultures by CRH antiserum or antagonist.
 
Anterior pituitaries were
dispersed with 0.1% collagenase in HAM-F10, plated at a density of
200,000 cells/well, and incubated at 37
 
8
 
C in DME, 10% FCS, 0.05 mg/
ml ascorbic acid (Sigma Chemical Co.), 100 U/ml penicillin, 100 U/ml
streptomycin, 10 mg/ml gentamycin, and 0.25 g/ml amphotericin B for
4 d. Except for ascorbic acid, all other reagents for cell culture were
purchased from Hyclone Ltd. (Cramlington, UK). On the day of the
experiment, wells were washed in serum-free medium containing
0.1% BSA for 1 h, before incubation with test agents. In the first set
of experiments, wells were incubated up to 3 h with CRH antiserum
(IgG Corp., Nashville, TN) at a final dilution of 1:300, 1:600, and
1:1,200 and medium samples were collected hourly for ACTH mea-
surement. Control wells were incubated in the presence of an equal
dilution of NRS. In the second set of experiments, wells were stimu-
lated either with 40 mM potassium chloride for 20 min or with 10 
 
m
 
M
forskolin for 3 h in the presence or absence of 50 nM 
 
a
 
-helical
CRH(9-41) or CRH antiserum (dilution 1:300 and 1:1,200). Both for-
skolin and the CRH antagonist were purchased from Sigma Chemical
Co. Medium was collected at the end of the incubation for ACTH
measurement. ACTH RIA was performed according to the manufac-
turer’s instructions (IgG Corp.) using tracer obtained from Amer-
sham International. Inter- and intraassay coefficient of variation were
6.9 and 6.4%, respectively.
 
Characterization of CRH immunoreactivity (CRH-IR) by HPLC.
 
For characterization of CRH-IR in medium, wells were incubated in
serum-free medium containing 0.1% BSA for 3 h. Medium from
three wells was then pooled and acidified with 1 N trifluoracetic acid
(TFA). Samples were applied to Sep-Pack C18 columns (Millipore
Corp., Bedford, MA) previously activated with 80% acetonitrile
(ACN) in 0.01 N TFA. Columns were washed with 0.01 N TFA and
samples eluted with 80% ACN in 0.01 N TFA. After lyophilization,
samples were reconstituted in 0.01 N TFA and applied to a Nucleosil
C18 reverse phase column (5 
 
m
 
m; 250 
 
3
 
 4.6 mm) attached to an 410
LC system (Perkin Elmer) and eluted with the following linear gradi-
ent: 0–35% ACN in 0.01 N TFA for 5 min, 35–65% ACN for 35 min,
and 65–80% ACN for 10 min at 1 ml/min. 1-min fractions were col-
lected, lyophilized, and reconstituted in CRH RIA buffer (phos-
phate-EDTA, pH 7.4, containing 0.02% sodium azide). An equal vol-
ume of serum-free medium not used for cell culture (
 
5 
 
blank) was
subjected to Sep-Pack and HPLC purification before loading the cul-
ture sample. After HPLC purification of anterior pituitary culture
medium, rat/human CRH(1-41) was loaded onto the column to deter-
mine the elution profile of the standard peptide. Reagents and mate-
rials for HPLC were purchased from Sigma Chemical Co. For quanti-
tative purposes, medium from single wells was lyophilized for direct
measurement of CRH-IR and protein content of each well was esti-
mated after extraction of attached cells (19) (Bio-Rad Laboratories,
Hercules, CA). CRH RIA was carried out at 4
 
8
 
C with a 100-fold dilu-
tion of the antibody in NRS and delayed addition of tracer. The
bound fraction was precipitated by the addition of a second antibody
and centrifugation (5,000 
 
g
 
 for 20 min at 4
 
8
 
C). Assay sensitivity was 2
pg/tube while half-maximal displacement occurred at 13 pg/tube. In-
traassay coefficient of variation was 7.8%. Rat/human CRH standard
and antibodies for RIA were obtained from IgG Corp. while 
 
125
 
I-
Tyr
 
0
 
-human/rat CRH was purchased from DuPont-NEN (Regens-
dorf, Switzerland).
 
Statistical analysis.
 
Each treatment was carried out in six wells
and experiments repeated at least twice. Student’s 
 
t
 
 test for unpaired
data was used for comparison of absolute concentrations between
treatments. Stimulated secretion was expressed as percent of basal se-
cretion with each agent and differences between treatments assessed
using Wilcoxon’s rank test. Data are given as mean
 
6
 
SEM.
 
Results
 
PCR amplification of mRNA obtained from the hypothalamus
and both the anterior and posterior pituitary using primers
specific to the rat CRH gene gave rise to a single 232-bp band
(Fig. 1). The band was clearly visible also in samples obtained
from adenohypophyseal dispersed cells (Fig. 1). Genomic con-
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tamination of RNA samples can be excluded since amplifica-
tion with GAPDH primers resulted only in the intron-less
240-bp fragment (data not shown). Further, no fragment was
amplified from samples subjected to either GAPDH or CRH
PCR amplification without prior reverse transcription (Fig. 1).
These results clearly indicate that the obtained bands derive
from mRNA. The identity of the fragments obtained by ampli-
fication with CRH primers was confirmed by restriction en-
zyme digestion and Southern blotting. Digestion of the CRH-
PCR products with PstI (restriction sites at bp 320 and 330 of
the CRH gene [14]) yielded a single 209-bp band whereas the
smaller fragments (10 and 14 bp) ran off the gel (Fig. 2). Diges-
tion with HaeIII (restriction sites at bp 401 and 496) gave rise
to two 95-bp fragments and a smaller sized (43-bp) fragment
not visible on gel (Fig. 2). On Southern blotting, a strong hy-
bridization signal was evident at the site of the 232-bp band in
both pituitary and hypothalamic samples (Fig. 3). PCR ampli-
fication of liver mRNA with primers for CRH as well as
Southern blotting failed to yield a like-sized band (Figs. 1 and
3). The presence of mRNA in these samples was proven
by amplification of the correct 240-bp band with GAPDH
primers.
In situ reverse transcription-PCR amplification with prim-
ers specific for the CRH gene resulted in the incorporation of
digoxigenin dUTP in single pituitary cells (Fig. 4, 
 
left
 
). The
specificity of the signal was ensured by failure to detect digoxi-
genin-labeled cells in negative controls (a representative sec-
tion is shown in Fig. 4, 
 
right
 
). Immunocytochemistry on the
same sections revealed colocalization of CRH mRNA expres-
sion and ACTH immunoreactivity (Fig. 4, 
 
left
 
), thus indicating
that CRH gene expression occurs in corticotropes. No red
stain could be detected in sections incubated with NRS instead
of the ACTH antibody (data not shown).
HPLC purification of anterior pituitary culture medium re-
vealed a clear peak of CRH-IR, coeluting with synthetic
CRH(1-41) (Fig. 5). The presence of a smaller peak at lower
mobility could indicate the presence of differently processed
CRH peptides or the CRH precursor. Test medium alone
(blank) did not contain CRH-IR. The prolonged period of at-
tachment and the repeated washes before collection of the me-
dium analyzed by HPLC nearly exclude contamination with
CRH internalized by corticotropes or contained in monocytes
or tissue macrophages. Measurement of CRH-IR in medium
from primary cultures after 3 h of incubation yielded a concen-
tration of 177.5
 
6
 
24.81 pg/200,000 cells (corresponding to
1.2
 
6
 
0.39 fmol/
 
m
 
g protein). By comparison, the same wells se-
creted 
 
z
 
 1.6 ng ACTH (
 
<
 
 14 fmol/
 
m
 
g protein). CRH-IR in-
creased significantly after a 20-min stimulation with potassium
(229.5
 
6
 
9.69 pg/200,000 cells vs. 141.9
 
6
 
21.86 pg/200,000 cells in
control wells,
 
 P 
 
, 
 
0.05).
Incubation of anterior pituitary cells with an antibody di-
Figure 1. PCR amplification products of mRNA from the hypothala-
mus (lane 6), anterior pituitary tissue (lanes 5 and 1), primary culture 
(lane 4), neurohypophysis (lane 3), and liver (lane 2) using primers 
specific to CRH. In lane 1, PCR amplification of anterior pituitary 
mRNA samples was carried out without prior reverse transcription.
Figure 2. Restriction enzyme digestion of CRH PCR products. Lane 
1, Hypothalamus; lane 2, PstI-digested hypothalamus; lane 3, PstI-
digested anterior pituitary; lane 4, HaeIII-digested hypothalamus; 
lane 5, HaeIII-digested anterior pituitary.
Figure 3. Southern 
blotting of CRH PCR 
products. Lane 1, Hypo-
thalamus; lane 2, ante-
rior pituitary; lane 3, 
liver.
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rected against CRH markedly reduced ACTH concentrations
in resting conditions compared with NRS-treated wells. This
effect was observed at all dilutions used and a representative
experiment is shown in Fig. 6. In agreement with previous
studies (20), ACTH basal secretion was largely unaffected by
 
a
 
-helical CRH(9-41) (data not shown). Stimulation with 40 mM
potassium and 10 
 
m
 
M forskolin induced a clear-cut increase in
ACTH, approximately twofold with potassium and fivefold
with forskolin. These increases were noticeably blunted by the
CRH antagonist (Fig. 7). The CRH antiserum clearly reduced
ACTH secretion after cell depolarization but did not appear to
affect its percent response to forskolin (Fig. 7). At closer scru-
tiny, however, the lack of an appreciable difference in percent
stimulated values is probably due to the low ACTH levels ob-
served with CRH antiserum alone by the third hour of incuba-
tion (1.45
 
6
 
0.12 vs. 3.12
 
6
 
0.61 ng/200,000 cells in NRS-treated
wells,
 
 P 
 
, 
 
0.05, Fig. 6). In fact, absolute ACTH concentrations
after forskolin stimulation were substantially lower in antise-
rum-treated wells compared with NRS-treated wells (6.7
 
6
 
0.27
vs. 14.1
 
6
 
1.10 ng/200,000 cells,
 
 P 
 
, 
 
0.05). On the whole, these
data can be taken to indicate an inhibitory effect of the CRH
antiserum on both potassium- and forskolin-stimulated ACTH
secretion.
 
Discussion
 
Paracrine and autocrine interactions within the anterior pitu-
itary have engendered an increasing interest, as attested by
several recent reviews (1, 3, 21). The anterior pituitary has
been found to harbor, apart from classical adenohypophyseal
hormones, several other peptides which participate in cell-to-
cell interactions and modulate hormonal secretion (2). In this
context, the synthesis of hypothalamic releasing factors, such
as thyrotropin-releasing hormone, growth hormone–releasing
hormone, somatostatin, and gonadotropin-releasing hormone
has been demonstrated recently in normal and tumoral ante-
rior pituitaries (5, 7, 9, 10, 12). These factors exert direct effects
on anterior pituitary hormone production and release as
well as on cell differentiation and growth, via their receptors
located on the pituicytes. Therefore, it is likely that small
amounts of locally produced hypothalamic hypophysiotropic
hormones can exert the actions of blood-borne neuropeptides.
However, these peptides are internalized by their target cells
and intrahypophyseal immunoreactivity could simply be due
to receptor-mediated endocytosis. It follows, therefore, that
demonstration of gene expression within the pituitary is crucial
to state that local synthesis of these neuropeptides occurs.
Figure 4. In situ reverse transcription-PCR amplification on dispersed anterior pituitary cells. (Left) PCR was carried out with primers specific 
for the CRH gene. Incorporation of digoxigenin dUTP gives rise to a blue-black signal by reaction with NBT/BCIP. Immunoreactivity for 
ACTH is visualized as a red stain with DAB (3630). (Right) Reverse transcription-PCR carried out without reverse transcriptase (negative con-
trol) followed by immunocytochemistry (3630).
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Upon the cloning of the CRH gene, several tissues had
been screened for its expression and CRH mRNA had been
detected in the pituitary (14). However, the whole gland had
been used in this study and no conclusions as to which pitu-
itary lobe expressed the CRH gene could be drawn and, as a
consequence, the possible functional importance of intrapitu-
itary CRH remained elusive.
We decided to search for CRH gene expression in the ante-
rior pituitary lobe using reverse transcription-PCR amplifica-
tion. This technique is capable of detecting minute amounts of
mRNA but, by virtue of its extreme sensitivity, is also suscepti-
ble to artifacts due to contamination with DNA or mRNA de-
rived from aspecific sources. Therefore, these issues were also
addressed.
PCR amplification of pituitary mRNA with primers spe-
cific to the rat CRH gene yielded a DNA fragment of the same
size as the one obtained from hypothalamic samples. Restric-
tion enzyme digestion and Southern blotting using a nested
probe confirmed that the band contained the expected se-
quence of the CRH gene. The likelihood of an artifact due
to genomic contamination was excluded by the results of
GAPDH PCR amplification and the absence of PCR products
when the amplification was carried out without prior reverse
transcription.
We also addressed the issue of which cells express the CRH
gene in the anterior pituitary. To this purpose, we carried out
in situ reverse transcription-PCR amplification followed by
Figure 5. HPLC purification of anterior pituitary culture medium. 
Filled circles stand for CRH concentrations while the dashed line
represents the ACN gradient. Arrow indicates elution fraction of rat/
human CRH(1-41).
Figure 6. Effect of CRH antiserum on basal ACTH secretion from 
anterior pituitary cells in vitro. Wells were incubated with the CRH 
antibody at final dilution of 1:300 (open circles). Control wells were 
incubated with an equal dilution of NRS (filled circles). *Statistical 
significance of P , 0.05 between antiserum and control wells at the 
same time point.
Figure 7. Effect of the CRH antagonist a-helical CRH(9-41) and 
CRH antiserum on stimulated ACTH secretion from anterior pitu-
itary cells in vitro. Results are expressed as percent of basal secretion 
with the same treatment (n 5 6 for each treatment). Empty bars indi-
cate control or NRS, whereas shaded bars correspond to secretion in 
presence of 50 nM a-helical CRH(9-41) or 1:300 antiserum. (A) Incu-
bation for 20 min with 40 mM potassium. (B) Incubation for 3 h with 
10 mM forskolin. *Statistical significance of P , 0.05 between agents 
and respective controls.
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immunocytochemistry on dispersed pituitary cells. Using this
approach we observed the presence of CRH mRNA in
ACTH-immunoreactive cells, thus demonstrating that the
CRH gene is expressed in corticotropes. Past cytochemical
studies had in fact detected CRH-IR in rat corticotropes and
not in other anterior pituitary cells but it had been postulated
to reflect receptor-mediated internalization (22). However, in
light of our findings, it seems likely that CRH-IR in cortico-
tropes is due to the synthesis of the peptide within these cells.
On the other hand, the specimens we used for this evaluation
are dispersed pituitary cells with the obvious loss of intercellu-
lar tissue and interstitial cells. Previous studies had observed
the presence of CRH mRNA in peripheral mononuclear cells
and tissue macrophages (23) and these cells could theoretically
contribute to the CRH PCR product in anterior pituitary tis-
sue samples. However, no DNA fragment could be detected
after amplification of liver mRNA with CRH primers, even on
Southern blotting. As we and others (24) failed to detect CRH
gene expression in the liver, a tissue quite rich in macrophages,
it seems unlikely that the band obtained in pituitary samples
arises from CRH mRNA contained in immune cells. On bal-
ance, our findings point to the corticotropes as the most likely
site of CRH gene expression within the anterior pituitary. We
also demonstrated the amplification of a CRH transcript from
posterior pituitary mRNA. Therefore, it follows that the signal
detected in whole pituitary samples on Northern blotting (14)
derived from both pituitary lobes.
The next step in our study was to evaluate whether anterior
pituitary cells can secrete the CRH peptide. To this purpose,
medium from anterior pituitary primary cultures was purified
by HPLC and the elution profile was determined. The major
peak of CRH-IR in culture medium coeluted with CRH(1-41),
the mature CRH peptide, indicating that anterior pituitary
cells can correctly process the precursor. Concentrations of
CRH-IR in culture medium were in the femtomolar range and
increased after stimulation with a depolarizing agent. By con-
trast, ACTH levels were z 10-fold higher. The low concentra-
tions of CRH support the concept of a locally acting peptide,
whereas the ACTH-secreting machinery is geared at higher
levels towards secretion into the blood stream.
Acting upon this results, we studied the effects of immu-
noneutralization and competitive antagonism of CRH on
ACTH secretion from anterior pituitary cells in vitro. Incuba-
tion with CRH antiserum induced a marked decrease in basal
and stimulated ACTH release. Basal ACTH secretion was un-
affected by the CRH antagonist a-helical CRH(9-41), in
agreement with the first published study on this compound
(20) whereas the ACTH response to both potassium and for-
skolin stimulation was blunted by the CRH antagonist. A pre-
vious study had failed to detect an inhibitory effect of a-helical
CRH(9-41) on forskolin-stimulated ACTH secretion (25).
This discrepancy is most likely due to the different cell density
and concentrations of antagonist used. As a-helical CRH(9-
41) competes with CRH for binding to its receptors (20) and
the binding affinity of the pituitary CRH receptor is different
for various ligands (26), the ratio of CRH antagonist to CRH
peptide appears to be crucial for the inhibitory action. As a
whole, our findings clearly indicate that CRH released by pitu-
itary cells contributes to corticotrope secretion in resting and
activated conditions.
The notion of a paracrine action of CRH has been demon-
strated in several tissues, first and foremost the placenta where
CRH influences blood flow, prostaglandin synthesis and, ulti-
mately, labor (27). CRH is also synthesized in other tissues of
the reproductive system, such as the ovaries (28), the en-
dometrium (29, 30), and the testis (31) and has been found to
modulate local cellular activities (32, 33). Also the adrenal
gland contains CRH (34) where it appears to act as a secreta-
gogue for corticosterone secretion (35) and medullary ACTH
secretion (36). Other important sites of CRH production, as
mentioned before, are lymphocytes and macrophages (23) and
the paracrine action of CRH on immune function has been es-
tablished clearly (37).
Various lines of evidence suggest that ACTH secretion can
be modulated, apart from blood-borne hormones, also by cell-
to-cell interactions (38, 39). First, several substances produced
by the anterior pituitary are known to influence corticotrope
secretion. Acetylcholine (40, 41) and chromogranin A (42), for
example, inhibit ACTH release whereas epidermal growth fac-
tor plays a role in the recruitment of corticotropes (43, 44).
Concurrently, experiments using a cytotoxic conjugate which
selectively destroys CRH target cells (45, 46) or in which the
distance between plated cells was manipulated (39) have
provided compelling evidence for paracrine communication
among distinct subtypes of corticotropes. Further, some inves-
tigators have postulated that the well known potentiation of
CRH responsiveness induced by vasopressin (47, 48) might be
mediated by paracrine interactions (46). On balance, para-
crine/autocrine communications play a significant role in mod-
ulating corticotrope activity and we now have identified CRH
as another possible player in this intrapituitary circuit. Hypo-
thetically, a given stimulus could act within the pituitary to in-
duce both ACTH and CRH release, thus amplifying the signal
driving corticotrope secretion.
In conclusion, our study provides definitive evidence that
the anterior pituitary synthesizes and secretes biologically ac-
tive CRH. The cells responsible for CRH gene expression in
the pituitary appear to be the corticotropes. Further, we dem-
onstrated that locally produced CRH effectively contributes to
ACTH secretion. Given this novel evidence, anterior pituitary
CRH could be involved in several aspects of both corticotrope
physiology and pathophysiology, such as Cushing’s disease or
isolated ACTH deficiency. Future studies will hopefully shed
light on the importance of this additional location of CRH
within the hypothalamic-pituitary-adrenal axis.
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